Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression

Anti-Cancer Drugs

Volumn 22, Issue 1, 2011, Pages 89-98

  Li, Ying Ying ^a   Chang, John W C ^a   Liu, Ying Chieh ^b   Wang, Cheng Hsu ^a   Chang, Hsin Ju ^a   Tsai, Meng Chun ^c   Su, Shiawhwa Paul ^d   Yeh, Kun Yun ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

Author keywords

cell cycle; cyclins; lung cancer; Ras protein; zoledronic acid

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B1; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; GERANYLGERANIOL; MEVALONIC ACID; PROTEIN P21; PROTEIN P27; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; ZOLEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ADENOCARCINOMA; ANIMALS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DIPHOSPHONATES; DITERPENES; DOWN-REGULATION; E2F TRANSCRIPTION FACTORS; IMIDAZOLES; LUNG NEOPLASMS; MEVALONIC ACID; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; PROTEIN TRANSPORT; RAS PROTEINS; RETINOBLASTOMA PROTEIN;

EID: 78650513866     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283400a05     Document Type: Article

References (45)

1. Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21:3150-3157.
2. Saba N, Khuri F. The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications. Oncology 2005; 68:10-17.
3. Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Monkkonen J, et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24 (5 Suppl):73S-79S.
4. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-589.
5. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000; 15:2211-2221.
6. Hiraga T,Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10:4559-4567.
7. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88:1971-1978.
8. Forsea AM, Muller C, Riebeling C, Orfanos CE, Geilen CC. Nitrogencontaining bisphosphonates inhibit cell cycle progression in human melanoma cells. Br J Cancer 2004; 91:803-810.
9. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, et al. Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 2006; 24:1145-1152.
10. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005; 104:2522-2529.
11. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
12. Howard CM, Claudio PP, De Luca A, Stiegler P, Jori FP, Safdar NM, et al. Inducible pRb2/p130 expression and growth-suppressive mechanisms: Evidence of a pRb2/p130, p27Kip1, and cyclin E negative feedback regulatory loop. Cancer Res 2000; 60:2737-2744.
13. Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-1512.
14. Zhang C, Lundgren K, Yan Z, Arango ME, Price S, Huber A, et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol Cancer Ther 2008; 7:818-828.
15. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, et al. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154:313-323.
16. 53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Sci 2004; 95:186-192.
17. Crick DC, Andres DA,Waechter CJ. Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation. Biochem Biophys Res Commun. 1997; 237:483-487.
18. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6:60. [Electronic resource]
19. Li YY, Chang JW, Chou WC, Liaw CC, Wang HM, Huang JS, et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008; 59:180-191.
20. Yuhas JM, Pazmino NH. Inhibition of subcutaneously growing line 1 carcinomas due to metastatic spread. Cancer Res 1974; 34:2005-2010.
21. Boulikas T. Phosphorylation of transcription factors and control of the cell cycle. Crit Rev Eukaryot Gene Expr 1995; 5:1-77.
22. Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 1998; 18:753-761.
23. Matsumoto S, Kimura S, Segawa H, Kuroda J, Yuasa T, Sato K, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47:31-39.
24. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-330.
25. Xiong W, Pestell RG, Watanabe G, Li J, Rosner MR, Hershenson MB. Cyclin D1 is required for S phase traversal in bovine tracheal myocytes. Am J Physiol 1997; 272 (6 Pt 1):L1205-L1210.
26. Ramakrishnan M, Musa NL, Li J, Liu PT, Pestell RG, Hershenson MB. Catalytic activation of extracellular signal-regulated kinases induces cyclin D1 expression in primary tracheal myocytes. Am J Respir Cell Mol Biol 1998; 18:736-740.
27. Ezhevsky SA, Nagahara H, Vocero-Akbani AM, Gius DR, Wei MC, Dowdy SF. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D: Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A 1997; 94:10699-10704.
28. Hosako M, Ogino T, Omori M, Okada S. Cell cycle arrest by monochloramine through the oxidation of retinoblastoma protein. Free Radic Biol Med 2004; 36:112-122.
29. Tyagi A, Agarwal C, Agarwal R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: Role in prostate cancer prevention. Mol Cancer Ther 2002; 1:525-532.
30. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional up-regulation of p27(Kip1). Blood 2002; 99:2199-2206.
31. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 2000; 28:1387-1404.
32. Mulcahy LS, Smith MR, Stacey DW. Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature 1985; 313:241-243.
33. Mittnacht S, Paterson H, Olson MF, Marshall CJ. Ras signalling is required for inactivation of the tumour suppressor pRb cell-cycle control protein. Curr Biol 1997; 7:219-221.
34. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, et al. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 1997; 386:177-181.
35. 21Cip1. Mol Cell Biol 1997; 17:5598-5611.
36. Kawada M, Kuwahara A, Nishikiori T, Mizuno S, Uehara Y. NA22598, a novel antitumor compound, reduces cyclin D1 levels, arrests cell cycle at G1 phase, and inhibits anchorage-independent growth of human tumor cells. Exp Cell Res 1999; 249:240-247.
37. Michalides RJ, Van de Brekel M, Balm F. Defects in G1-S cell cycle control in head and neck cancer: A review. Head Neck 2002; 24:694-704.
38. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113:364-371.
39. McGuire TF, Qian Y, Vogt A, Hamilton AD, Sebti SM. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J Biol Chem 1996; 271:27402-27407.
40. Denoyelle C, Hong L, Vannier JP, Soria J, Soria C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88:1631-1640.
41. Berenson J, Ravera C, Ma P, Deckert F, Sasaki Y, Saeki T, et al. Population pharmacokinetics (PK) of Zometa. Proc Am Soc Clin Oncol 2000; 19:209a. (abstr 814)
42. Papapoulos SE. Bisphosphonates: How do they work? Best Prac Res 2008; 22:831-847.
43. Losada I, Sartori L, Di Gianantonio E, Zen M, Clementi M, Doria A. Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age? Autoimmun Rev 2010; 9:547-552.
44. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997; 57:3890-3894.
45. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-2714.